The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation for opioid use disorder and speed up availability of treatment, according to a press release from the manufacturer.
1d
Hosted on MSNFDA approves first opioid-free painkiller in over two decadesThe U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.
Palghar: The Union health ministry has stopped operations and production of Aveo Pharmaceuticals Ltd. (Aveo) following reports that the company had been exporting unapproved drug combinations containing Tapentadol and Carisoprodol to certain West African nations.
Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.
FDA officials have identified nine more companies allowed to manufacture and export a banned, lethal drug combination linked to the opioid crisis in W
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive like opioids.
The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say Journavx is an important alternative because the power of opioids helped fuel an overdose epidemic and a surge in fentanyl use.
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford and Chief of the Division of Pain Medicine at the university. Dr. Mackey, welcome to Science Friday.
Advancements have been made in the pain management field that have successfully found FDA approved alternatives to traditional opioids
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid
Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid initiation protocol and alternative injection sites,
Some results have been hidden because they may be inaccessible to you
Show inaccessible results